|
시장보고서
상품코드
2055222
세포 리프로그래밍 시장 : 제품별Cell Reprogramming Market, By Product (Instruments, By Cell Type, By Source of Cells, By Technology, By Application, By End User, By Geography ) |
||||||
세포 리프로그래밍 시장은 2026년 4억 3,710만 달러로 추정되고, 2033년에 7억 8,870만 달러에 이를 전망입니다. 또한, 2026-2033년 CAGR 8.8%를 기록할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 4억 3,710만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.80% | 2033년 시장 규모 예측 : | 7억 8,870만 달러 |
세계 세포 리프로그래밍 시장은 재생의학 및 생명공학 분야의 혁신적인 개척 분야로서, 연구자와 임상의가 세포 치료 및 질환 치료에 접근하는 방식을 근본적으로 변화시키고 있습니다. 분화 세포를 다능성 상태로 되돌리거나, 직접 다른 세포 유형으로 전환하는 과정인 세포 리프로그래밍은 그 어느 때보다 새로운 치료 가능성을 열어주는 기반 기술로 부상하고 있습니다. 이러한 첨단 생물학적 기법에는 iPS 세포(인공 다능성 줄기세포)의 제작, 직접 리프로그래밍, 전분화 과정 등 다양한 연구 기법이 포함되어 있으며, 각각은 맞춤형 의료의 응용 분야에서 고유한 장점을 제공합니다.
이 시장은 전 세계 학술 기관, 제약 회사, 생명공학 기업에서 세포 리프로그래밍을 촉진하는 연구 도구, 시약, 장비, 서비스로 구성된 종합적인 생태계를 아우르고 있습니다. 정밀 의학 및 재생 의학에 대한 관심이 높아지는 가운데, 세포 리프로그래밍 기술은 신약 개발 파이프라인, 질환 모델링 플랫폼, 그리고 기존 치료가 어려웠던 질환에 대한 잠재적인 치료 개입 수단으로 점점 더 통합되고 있습니다. 첨단 유전자 편집 기술, 개선된 리프로그래밍 프로토콜, 세포 가소성 메커니즘에 대한 이해의 심화가 결합되어, 이 시장은 차세대 의료 혁신의 최전선에 위치하며, 여러 치료 분야에 걸친 치료 패러다임의 재구성을 약속하고 있습니다.
시장 역학
세계 세포 리프로그래밍 시장은 전반적인 견실한 성장세를 뒷받침하는 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 만성 질환, 유전성 질환, 노화 관련 질환의 유병률 증가는 세포 리프로그래밍 기술이 독자적으로 대응할 수 있는 혁신적인 치료 접근법에 대한 큰 수요를 창출하고 있습니다. 재생의학 연구 개발에 대한 투자 확대는 지원적인 정부 자금 지원 정책 및 유리한 규제 체계와 맞물려 시장 발전을 크게 가속화하고 있습니다. 비통합적 접근법이나 화학적으로 정의된 프로토콜을 포함한 리프로그래밍 연구 기법의 기술적 진보는 효율성을 높이는 동시에 안전성 우려를 완화함으로써, 상업적 실현 가능성을 확대되고 있습니다.
제약 산업에서 맞춤형 의료 및 환자 맞춤형 치료 솔루션에 대한 관심이 높아짐에 따라, iPS 세포(iPSC)를 활용한 약물 스크리닝 및 독성 검사 플랫폼의 도입이 가속화되고 있습니다. 그러나 시장 성장에는 세포 치료와 관련된 복잡한 규제 절차, 일관된 리프로그래밍 효율을 달성하기 위한 중대한 기술적 과제, 전문적인 실험실 인프라 구축에 수반되는 막대한 비용과 같은 뚜렷한 제약 요인이 존재합니다. 줄기세포 연구와 관련된 윤리적 고려 사항 외에도, 리프로그래밍 프로토콜 간의 표준화가 미흡한 점도 시장 진입의 또 다른 장벽이 되고 있습니다. 리프로그래밍된 세포의 유전체 불안정성 및 종양 형성 능력과 관련된 안전성 우려는 여전히 규제 및 상업적 측면에서 과제로 남아 있습니다. 그럼에도 불구하고, 특히 질환 모델링, 신약 개발 가속화, 기존 세포 치료제 개발 분야의 활용 범위 확대를 통해 새로운 기회가 큰 성장 잠재력을 지니고 있습니다. 생명공학 기업과 대형 제약사의 전략적 제휴는 기술 이전과 상용화의 길을 열어줍니다. 신흥 시장에서의 도입 확대와 더불어, 재생의학의 장점에 대한 인식이 높아짐에 따라 산업 관계자들에게 새로운 수익원과 시장 확대의 기회가 창출되고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 세포 리프로그래밍 시장의 주요 기업들을 분석했습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 전 세계 세포 리프로그래밍 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 세포 리프로그래밍 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 세포 리프로그래밍 시장 : 제품별, 2021-2033년
제5장 세계의 세포 리프로그래밍 시장 : 세포 유형별, 2021-2033년
제6장 세계의 세포 리프로그래밍 시장 : 세포 유래별, 2021-2033년
제7장 세계의 세포 리프로그래밍 시장 : 기술별, 2021-2033년
제8장 세계의 세포 리프로그래밍 시장 : 용도별, 2021-2033년
제9장 세계의 세포 리프로그래밍 시장 : 최종사용자별, 2021-2033년
제10장 세계의 세포 리프로그래밍 시장 : 지역별, 2021-2033년
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌과 조사 방법
LSH 26.06.23Cell Reprogramming Market is estimated to be valued at USD 437.1 Mn in 2026 and is expected to reach USD 788.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 437.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.80% | 2033 Value Projection: | USD 788.7 Mn |
The global cell reprogramming market represents a revolutionary frontier in regenerative medicine and biotechnology, fundamentally transforming how researchers and clinicians approach cellular therapy and disease treatment. Cell reprogramming, the process of converting differentiated cells back to a pluripotent state or directly into other cell types, has emerged as a cornerstone technology enabling unprecedented therapeutic possibilities. This sophisticated biological technique encompasses various methodologies including induced pluripotent stem cell (iPSC) generation, direct reprogramming, and trans differentiation processes, each offering unique advantages for personalized medicine applications.
The market encompasses a comprehensive ecosystem of research tools, reagents, instruments, and services that facilitate cellular reprogramming across academic institutions, pharmaceutical companies, and biotechnology firms worldwide. With growing emphasis on precision medicine and regenerative therapies, cell reprogramming technologies are increasingly being integrated into drug discovery pipelines, disease modeling platforms, and potential therapeutic interventions for previously untreatable conditions. The convergence of advanced gene editing technologies, improved reprogramming protocols, and enhanced understanding of cellular plasticity mechanisms has positioned this market at the forefront of next-generation medical innovations, promising to reshape treatment paradigms across multiple therapeutic areas.
Market Dynamics
The global cell reprogramming market is propelled by several compelling drivers that collectively fuel its robust expansion trajectory. The increasing prevalence of chronic diseases, genetic disorders, and age-related conditions creates substantial demand for innovative therapeutic approaches that cell reprogramming technologies uniquely address. Growing investments in regenerative medicine research, coupled with supportive government funding initiatives and favorable regulatory frameworks, significantly accelerate market development. Technological advancements in reprogramming methodologies, including non-integrative approaches and chemically-defined protocols, enhance efficiency while reducing safety concerns, thereby expanding commercial viability.
The pharmaceutical industry's intensifying focus on personalized medicine and patient-specific therapeutic solutions drives adoption of iPSC-based drug screening and toxicity testing platforms. However, market growth faces notable restraints including complex regulatory pathways for cell-based therapies, substantial technical challenges in achieving consistent reprogramming efficiency, and significant cost barriers associated with establishing specialized laboratory infrastructure. Ethical considerations surrounding stem cell research, along with limited standardization across reprogramming protocols, create additional market entry barriers. Safety concerns regarding genomic instability and tumorigenic potential of reprogrammed cells continue to pose regulatory and commercial challenges. Nevertheless, emerging opportunities present substantial growth potential, particularly through expanding applications in disease modeling, drug discovery acceleration, and development of off-the-shelf cellular therapies. Strategic partnerships between biotechnology companies and pharmaceutical giants facilitate technology transfer and commercialization pathways. Growing adoption in emerging markets, coupled with increasing awareness of regenerative medicine benefits, creates new revenue streams and market expansion opportunities for industry participants.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cell reprogramming market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Thermo Fisher Scientific, Merck KGaA, Takara Bio Inc, Lonza Group, FUJIFILM Cellular Dynamics, StemCell Technologies, REPROCELL Inc, Astellas Pharma, Fate Therapeutics, Cynata Therapeutics, Pluri Inc, ViaCyte Inc, BlueRock Therapeutics, Century Therapeutics, and Editas Medicine.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cell reprogramming market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell reprogramming market.
Market Segmentation
- Product Insights (Revenue, USD Mn, 2021 - 2033)
- Instruments
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (COa,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Cell Type Insights (Revenue, USD Mn, 2021 - 2033)
- Somatic Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cancer Stem Cells
- Mesenchymal Stem Cell
- Source of Cells Insights (Revenue, USD Mn, 2021 - 2033)
- Human Cells
- Animal Cells
- Technology Insights (Revenue, USD Mn, 2021 - 2033)
- Sendai Virus-based Reprogramming
- mRNA Reprogramming
- Episomal Reprogramming
- Small Molecule-based Reprogramming
- CRISPR or Cas9-based Reprogramming
- Other Reprogramming Technologies
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Stem Cell Research
- Disease Modeling
- Toxicology Testing
- Drug Screening
- Regenerative Medicine
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Contract Research Organizations (CROs)
- Government and Non-profit Organizations
- Others (Academic and Research Institutions, etc.)
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cell Reprogramming Market, By Product
- Global Cell Reprogramming Market, By Cell Type
- Global Cell Reprogramming Market, By Source of Cells
- Global Cell Reprogramming Market, By Technology
- Global Cell Reprogramming Market, By Application
- Global Cell Reprogramming Market, By End User
- Global Cell Reprogramming Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cell Reprogramming Market, By Product, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Instruments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (COa,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Reprogramming Workstations
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Cell Reprogramming Market, By Cell Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Somatic Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Embryonic Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Adult Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cancer Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Mesenchymal Stem Cell
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Cell Reprogramming Market, By Source of Cells, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Human Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Animal Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Cell Reprogramming Market, By Technology, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Sendai Virus-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- mRNA Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Episomal Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Small Molecule-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- CRISPR or Cas9-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Other Reprogramming Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Cell Reprogramming Market, By Application, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Stem Cell Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Drug Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
9. Global Cell Reprogramming Market, By End User, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Goverment and Non-profit Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (Academic and Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
10. Global Cell Reprogramming Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takara Bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lonza Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Cellular Dynamics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- StemCell Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- REPROCELL Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cynata Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pluri Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViaCyte Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BlueRock Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Century Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Editas Medicine
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
